entertainment -WSS

entertainment

author：entertainment 2025-09-06 01:58:19 - browse：27147

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Astellas still sees hope in its gene therapy after four deaths

hotspot

WSS

Weight loss drug costs may need more research, senator suggests

Feng Zhang CRISPR delivery startup lays off quarter of staff

Poor hospice wound care hurts patients and families

Wegovy, Zepbound and weight loss drugs that preserve muscle

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

3 medical device trends to watch in 2024

focus

entertainment

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA's Woodcock to retire early next year

Cancer drug shortages should be causing more outrage

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Medical leaders decry Supreme Court decision on affirmative action

Morphosys mixed study results for blood cancer drug

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

J&J to buy cancer drug developer Ambrx Biopharma

Peter Hotez and the public health issue of online harassment

Weight loss drug costs may need more research, senator suggests

focus

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The biotech scorecard for Q1: 17 stock

PBM reforms clear House panel

A daunting task: navigating dual Medicare, Medicaid eligibility

PBM reforms clear House panel

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

knowledge

hotspot

hotspot

Wikipedia